Compare with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES VENUS REMEDIES ALKEM LABORATORIES/
VENUS REMEDIES
 
P/E (TTM) x 25.0 -7.6 - View Chart
P/BV x 6.0 0.5 1,187.9% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 ALKEM LABORATORIES   VENUS REMEDIES
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
VENUS REMEDIES
Mar-18
ALKEM LABORATORIES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs2,720126 2,160.4%   
Low Rs1,66061 2,717.4%   
Sales per share (Unadj.) Rs697.9301.8 231.2%  
Earnings per share (Unadj.) Rs96.1-24.9 -386.5%  
Cash flow per share (Unadj.) Rs117.32.5 4,608.2%  
Dividends per share (Unadj.) Rs25.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs515.2293.3 175.7%  
Shares outstanding (eoy) m119.5712.34 969.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.10.3 1,013.0%   
Avg P/E ratio x22.8-3.8 -606.1%  
P/CF ratio (eoy) x18.736.7 50.8%  
Price / Book Value ratio x4.30.3 1,333.4%  
Dividend payout %26.00-   
Avg Mkt Cap Rs m261,8791,154 22,697.3%   
No. of employees `00014.30.9 1,549.3%   
Total wages/salary Rs m15,055393 3,829.8%   
Avg. sales/employee Rs Th5,822.64,026.1 144.6%   
Avg. wages/employee Rs Th1,050.5425.0 247.2%   
Avg. net profit/employee Rs Th802.0-331.8 -241.7%   
INCOME DATA
Net Sales Rs m83,4443,724 2,240.6%  
Other income Rs m1,04223 4,632.0%   
Total revenues Rs m84,4863,747 2,255.0%   
Gross profit Rs m14,734395 3,732.0%  
Depreciation Rs m2,528338 747.1%   
Interest Rs m651354 183.6%   
Profit before tax Rs m12,598-275 -4,576.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,10532 3,496.2%   
Profit after tax Rs m11,493-307 -3,744.9%  
Gross profit margin %17.710.6 166.6%  
Effective tax rate %8.8-11.5 -76.4%   
Net profit margin %13.8-8.2 -167.1%  
BALANCE SHEET DATA
Current assets Rs m54,9602,638 2,083.7%   
Current liabilities Rs m32,4332,305 1,407.3%   
Net working cap to sales %27.08.9 301.9%  
Current ratio x1.71.1 148.1%  
Inventory Days Days80135 58.7%  
Debtors Days Days7246 155.7%  
Net fixed assets Rs m32,7104,871 671.6%   
Share capital Rs m239123 193.8%   
"Free" reserves Rs m61,3683,496 1,755.5%   
Net worth Rs m61,6073,619 1,702.3%   
Long term debt Rs m1,5921,374 115.9%   
Total assets Rs m99,4337,509 1,324.3%  
Interest coverage x20.40.2 9,132.6%   
Debt to equity ratio x00.4 6.8%  
Sales to assets ratio x0.80.5 169.2%   
Return on assets %12.20.6 1,934.6%  
Return on equity %18.7-8.5 -220.0%  
Return on capital %21.01.6 1,325.1%  
Exports to sales %19.10-   
Imports to sales %3.013.9 21.5%   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483517 480.7%   
Fx inflow Rs m16,0610-   
Fx outflow Rs m2,483517 480.7%   
Net fx Rs m13,578-517 -2,628.9%   
CASH FLOW
From Operations Rs m5,851514 1,137.4%  
From Investments Rs m-7,414-123 6,022.3%  
From Financial Activity Rs m792-387 -204.5%  
Net Cashflow Rs m-7314 -17,407.1%  

Share Holding

Indian Promoters % 66.9 32.9 203.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 0.2 18,388.9%  
FIIs % 0.0 0.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 66.4 -  
Shareholders   68,381 20,121 339.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

Buzzing Sectors Before Budget 2021(Fast Profits Daily)

Jan 12, 2021

The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.

Here's Why Smallcaps Could Be Your Best Investment in 2021(Profit Hunter)

Jan 12, 2021

Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 25, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS